Bone Marrow Purging in Acute Leukemia with Alkyl-Lysophospholipids: A New Family of Anticancer Drugs

References

• Lee T.-C., Snyder F. Function, metabolism, and regulation of platelet activating factor and related ether lipids. Phospholipids and Cellular Regulation, J.F. Kuo. CRC Press, Boca Raton, FL 1985; vol. 2: 2–39
   Google Scholar
• Pirotzky E., Hosford D., Mencia-Huerta J.-M., Bra-Quet P. Role of platelet-activating factor in immune process. Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury, K.V. Honn, L.J. Marnett, S. Nigam, T.L. Waldon, Jr. Kluwer Academic Publishers, Norwell, MA 1991; 427–437
   Google Scholar
• Andreesen R., Modolell M., Weltzien H.U., Eibl H., Common H.H., Lohr G.W., Munder P.G. Selective destruction of human leukemic cells by alkyl-lyso-phospholipids. Cancer Res. 1978; 38: 3894–3899
   PubMed Web of Science ®Google Scholar
• Modolell M., Andreesen R., Pahlke W., Brugger U., Munder P.G. Disturbance of phospholipid metabolism during the selective destruction of tumor cells induced by alkyl-lysophospholipids. Cancer Res. 1979; 39: 4681–4686
   PubMed Web of Science ®Google Scholar
• Vogler W.R., Whigham E.A., Somberg L.B., Long R.C., Jr., Winton E.F. The effect of alkyl-lyso phospholipids on tritiated thymidine incorporation and clon-ogenicity in vitro of normal and leukemic human cells. Exp. Hematol. 1984; 12: 569–574
   PubMed Web of Science ®Google Scholar
• Hoffman D.R., Hajdu J., Snyder F. Cytotox-icity of platelet activating factor and related alkyl-phospho-lipid analogs in human leukemia cells, polymorphonuclear neutrophils, and skin fibroblasts. Blood 1984; 63: 545–552
   PubMed Web of Science ®Google Scholar
• Schick H.D., Berdel W.E., Fromm M., Fink U., Jehn U., Ulm K., Reichert A., Eibl H., Unger C., Rastetter J. Cytotoxic effects of ether lipids and derivatives in human non-neoplastic bone marrow cells and leukemic cells in vitro. Lipids 1987; 22: 904–910
   PubMed Web of Science ®Google Scholar
• Verdonck L.F., Witteveen E.O., van Heugten H.G., Rozemuller E., Rijksen G. Selective killing of malignant cells from leukemic patients by alkyl-lysophospho-lipid. Cancer Res. 1990; 50: 4020–4025
   PubMed Web of Science ®Google Scholar
• Helfman D.M., Barnes K.C., Kinkade J.M., Jr., Vogler W.R., Shoji M., Kuo J.F. Phospholipid-sen-sitive Ca2+-dependent protein phosphorylation system in various types of leukemic cells from human patients and in hu man leukemic cell lines HL60 and K562, and its inhibition by alkyl-lysophospholipid. Cancer Res. 1983; 43: 2955–2961
   PubMed Web of Science ®Google Scholar
• Van Blitterswijk W.J., van der Bend R.L., Kramer I.M., Verhoeven A.J., Hilkmann H., de Widt J. A metabolite of an antineoplastic ether phospholipid may inhibit transmembrane signalling via protein kinase C. Lipids 1987; 22: 842–846
   PubMed Web of Science ®Google Scholar
• Powis G., Seewald M.J., Gratas C., Melder D., Riebow J., Modest E.J. Selective inhibition of phospha-tidylinositol phospholipase C by cytotoxic ether lipid analogues. Cancer Res. 1992; 52: 2835–2840
   PubMed Web of Science ®Google Scholar
• Lohmeyer M., Workman P. Antitumor ether lip ids and platelet-activating factor analogues have different cytotoxic profiles and calcium mobilizing effects—A structure-activity study. Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury, S. Nigam, K.V. Honn, L.J. Marnett, T.L. Walden, Jr. Kluwer Academic Publishers, Norwell, MA 1993; 699–702
   Google Scholar
• Seewald M.J., Olsen R.A., Sehgal I., Melder D.C., Modest E.J., Powis G. Inhibition of growth factor-dependent inositol phosphate Ca2+ signaling by antitumor ether lipid analogues. Cancer Res. 1990; 50: 4458–4463
   PubMed Web of Science ®Google Scholar
• Zheng B., Oishi K., Shoji M., Eibl H., Berdel W.E., Hajdu J., Vogler W.R., Kuo J.F. Inhibition of protein kinase C, (sodium plus potassium)-activated adeno-sine triphosphatase, and sodium pump by synthetic phospho lipid analogues. Cancer Res. 1990; 50: 3025–3031
   PubMed Web of Science ®Google Scholar
• Kiss Z., Deli E., Vogler W.R., Kuo J.F. An-tileukemic agent alkyl-lysophospholipid regulates phosphor ylation of distinct proteins in HL60 and K562 cells and dif ferentiation of HL60 cells promoted by phorbol ester. Biochem. Biophys. Res. Comm. 1987; 142: 661–666
   PubMed Web of Science ®Google Scholar
• Shoji M., Raynor R.L., Berdel W.E., Vogler W.R., Kuo J.F. Effects of thioether phospholipid BM 41.440 on protein kinase C and phorbol ester-induced differentiation of human leukemia HL60 and KG-1 cells. Cancer Res. 1988; 48: 6669–6673
   PubMed Web of Science ®Google Scholar
• Honma Y., Kasukabe T., Hozumi T., Tsushima S., Nomura H. Induction of differentiation of cultured human and mouse myeloid leukemia cells by alkyl-lysophos pholipids. Cancer Res. 1981; 41: 3211–3216
   PubMed Web of Science ®Google Scholar
• Vogler W.R., Whigham E., Bennett W.D., Olson A.C. The effect of alkyl-lysophospholipids on phos-phatidylcholine biosynthesis in leukemic cell lines. Exp. He matol. 1985; 13: 629–633
   PubMed Web of Science ®Google Scholar
• Lands W. E. M., Hart P. Metabolism of glycer-olipids. VI. Specificities of acyl coenzyme A: Phospholipid acyltransferases. J. Biol. Chem. 1965; 240: 1905–1911
   PubMed Web of Science ®Google Scholar
• Vogler W.R., Olson A.C. The effect of alkyl-lysophospholipids on phosphatidylcholine biosynthesis. The Cell Membrane as a Target for Tumor Therapy. Aktuelle On-kologie, C. Unger, H. Eibl, G.A. Nagel. W. Zuckschwerdt Verlag, MunichGermany 1987; Vol. 34: 80–92
   Google Scholar
• Kennedy E.P., Weiss S.B. The function of cy-tidine coenzymes in the biosynthesis of phospholipids. J. Biol. Chem. 1956; 222: 193–214
   PubMed Web of Science ®Google Scholar
• Vogler W.R., Goodwyn D., Sergenton S. The effect of edelfosine on de novo phospholipid biosynthesis in leukemic cell lines. Proceedings of American Association for Cancer Research. 1993; vol. 34: 353
   Google Scholar
• Tidwell T., Guzman G., Vogler W.R. The effects of alkyl-lysophospholipids on leukemic cell lines. I. Dif ferential action on two human leukemic cell lines HL60 and K562. Blood 1981; 57: 794–797
   PubMed Web of Science ®Google Scholar
• Long R.C., Jr., Small W.C., Brynes R.K., Tidwell T., Goldstein J.H., Vogler W.R. Effects of alkyl-lysophospholipids on human leukemic cell lines measured by nuclear magnetic resonance. Cancer Res. 1983; 43: 770–775
   PubMed Web of Science ®Google Scholar
• Vogler W.R., Olson A.C., Shoji M., Li H., Kiss Z., Kuo J.F. Effect of alkyl-lysophospholipids in phosphatidylcholine biosynthesis in leukemic cell lines. The Pharmacological Effects of Lipids II, J.J. Kabara. Lauricidin, Inc., Galena, IL 1989; 314–329
   Google Scholar
• Hoffman D.R., Hoffman L.H., Snyder F. Cy-totoxicity and metabolism of alkyl phospholipid analogues in neoplastic cells. Cancer Res. 1986; 46: 5803–5809
   PubMed Web of Science ®Google Scholar
• Van Blitterswijk W.J., Hilkmann H., Storme G.A. Accumulation of an alkyl-lysophospholipid in tumor cell membranes affects membrane fluidity and tumor cell invasion. Lipids 1987; 22: 820–823
   PubMed Web of Science ®Google Scholar
• Bazill G.W., Dexter T.M. Role of endocytosis in the action of ether lipids on WEHI-3B, HL60, and FDCP-mix A4 cells. Cancer Res. 1990; 50: 7505–7512
   PubMed Web of Science ®Google Scholar
• Kelley E.E., Modest E.J., Burns C.P. Uni directional membrane uptake on the ether lipid antineoplastic agent edelfosine by L1210 cells. Biochem. Pharmacol. 1993, In press
   PubMed Web of Science ®Google Scholar
• Fromm M., Berdel W.E., Schick H.D., Fink U., Pahlke W., Bicker U., Reichert A., Rastetter J. Anti-neoplastic activity of the thioether lysophospholipid derivative BM 41.440 in vitro. Lipids 1987; 22: 916–918
   PubMed Web of Science ®Google Scholar
• Vogler W.R., Olson A.C., Okamoto S., Somberg L.B., Glasser L. Experimental studies on the role of alkyl-lysophospholipids in autologous bone marrow trans plantation. Lipids 1987; 22: 919–923
   PubMed Web of Science ®Google Scholar
• Glasser L., Somberg L.B., Vogler W.R. Purg ing murine leukemic marrow with alkyl-lysophospholipids. Blood 1984; 64: 1288–1291
   PubMed Web of Science ®Google Scholar
• Vogler W.R., Somberg L.B., Glasser L. Effect of cryopreservation on purging of leukemic marrow with al kyl-lysophospholipids. Exp. Hematol. 1987; 15: 360–364
   PubMed Web of Science ®Google Scholar
• Okamoto S., Olson A.C., Vogler W.R., Winton E.F. Purging leukemic cells from simulated human re mission marrow with alkyl-lysophospholipid. Blood 1987; 69: 1381–1387
   PubMed Web of Science ®Google Scholar
• Berdel W.E., Schlehe H., Fink U., Emmerich B., Mau-Back P.A., Emslander H.P., Daum S., Rastetter J. Early tumor and leukemia response to alkyl-lysophos pholipids in a phase I study. Cancer 1982; 50: 2011–2015
   PubMed Web of Science ®Google Scholar
• Vogler W.R., Berdel W.E., Olson A.C., Winton E.F., Heffner L.T., Gordon D.G. Autologous bone marrow transplantation in acute leukemia with marrow purged with alkyl-lysophospholipid. Blood 1992; 80: 1423–1429
   PubMed Web of Science ®Google Scholar
• Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53: 457–481
   Web of Science ®Google Scholar
• Yeager A.M., Kaizer H., Santos G.W., Saral R., Col-Vin O.M., Stuart R.K., Braine H.G., Burke P.J., Am-Binder R.F., Bums W.H., Fuller D.J., Davis J.M., Karp J.E., May S., Rowley S.D., Sensenbrenner L.L., Vogelsang G.B., Wingard J.R. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo treatment with 4-hydroperoxycyclo-phosphamide. N. Engl. J. Med. 1986; 315: 141–147
   PubMed Web of Science ®Google Scholar
• Gorin N.C., Aegerter P., Auvert B., Meloni B., Gold-Stone A.H., Burnett A., Carella A., Körbling M., Herve P., Maraninchi D., Löwenberg R., Verdonck L.F., de Planque M., Hermans J., Helbig W., Porcellini A., Riz-Zoli V., Alesandrino E.P., Franklin I.M., Reiffers J., Colleselli P., Goldman J.M. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: A European survey of the role of marrow purging. Blood 1990; 75: 1606–1614
   PubMed Web of Science ®Google Scholar
• Chopra R., Goldstone A.H., McMillan A.K., Powles R., Smith A.G., Prentice H.G., Reid C., Marcus R., Bell A., Milligan D., McCarthy D., Morgenstern G., Bar nard D. Successful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan/cyclophosphamide and un-purged marrow: The British Autograft Group Experience. J. Clin. Oncol. 1991; 9: 1840–1847
   PubMed Web of Science ®Google Scholar
• McMillan A.K., Goldstone A.H., Linch D.C., Gribben J.G., Patterson K.G., Richards J. D. M., Franklin I., Boughton B.J., Milligan D.W., Leyland M., Hutchison R.M., Newland A.C. High-dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia. Blood 1990; 76: 480–488
   PubMed Web of Science ®Google Scholar
• Körbling M., Hunstein W., Fliedner T.M., Cayeux S., Dorken B., Fehrentz D., Haas R., Ho A.D., Keilholz U., Knauf W., Konig A., Mende U., Pezzutto A., von Reumont J., Wolf G.K., Wannenmacher M., zum Winkel K., Rother K. Disease-free survival after autologous bone marrow transplantation in patients with acute my-elogenous leukemia. Blood 1989; 74: 1898–1904
   PubMed Web of Science ®Google Scholar
• Büchner T., Hiddemann W., Loffler G., Gassmann W., Maschmeyer G., Heit W., Hossfeld D., Weh H., Ludwig W.-D., Thiel E., Nowrousian M., Aul C., Lengfelder E., Lathan B., Mainzer K., Urbanitz D., Emmerich B., Mid-Delhoff G., Donhuijsen-Ant H.R., Hellriegel H.-P., Heinecke A. Improved cure rate by very early intensification combined with prolonged maintenance chemother apy in patients with acute myeloid leukemia: data from the AML Cooperative Group. Semin. Hematol. 1991; 28: 76–79
   PubMed Web of Science ®Google Scholar
• Schiller G., Gajewski J., Territo M., Nimer S., Lee M., Belin T., Champlin R. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 1992; 80: 2977–2982
   PubMed Web of Science ®Google Scholar
• Omura G., Raney M. Long-term survival in adult acute lymphoblastic leukemia: follow-up of a Southeastern Cancer Study Group trial. J. Clin. Oncol. 1985; 3: 1053–1058
   PubMed Web of Science ®Google Scholar
• Hoelzer D., Thiel E., Loffler H., Büchner T., Ganser A., Heil G., Koch P., Freund M., Diedrich H., Ruhl H., Maschmeyer G., Lipp T., Nowrousian M.R., Burkert M., Gereck D., Pralle H., Muller U., Lunscken C., Fulle H., Ho A.D., Kuchler R., Busch F.W., Schneider W., Gorg C., Emmerich B., Braumann D., Vaupel H.A., von Pa-Leske A., Bartels H., Neiss A., Messerer D. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988; 71: 123–131
   PubMed Web of Science ®Google Scholar
• Gaynor J., Chapman D., Little C., McKenzie S., Miller W., Andreeff M., Arlin Z., Berman E., Kempin S., Gee T., Clarkson B. A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lym phoblastic leukemia: The Memorial Hospital experience since 1969. J. Clin. Oncol. 1988; 6: 1014–1030
   PubMed Web of Science ®Google Scholar
• Hussein K.K., Dahlberg S., Head D., Waddell C.C., Dabich L., Weick J.K., Momson F., Saiki J.H., Metz E., Rivkin S.E., Grever M.R., Boldt D., for the Southwestern Oncology Group. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood 1989; 73: 57–63
   PubMed Web of Science ®Google Scholar
• Ramsay N., LeBien T., Nesbit M., McGlave P., Weis-Dorf D., Kenyon P., Hurd D., Goldman A., Kim T., Kersey J. Autologous bone marrow transplantation for patients with acute lymphoblastic leukemia in second or sub sequent remission: Results of bone marrow treated with monoclonal antibodies BA-1, BA-2, and BA-3 plus complement. Blood 1985; 66: 508–513
   PubMed Web of Science ®Google Scholar
• Simonsson B., Burnett A.K., Prentice H.G., Hann I.H., Brenner M.K., Gibson B., Grob J.P., Lönnerholm G., Morrison A., Smedmyr B., Todd A., Öberg G., Gilmore M., Campana D., Tötterman T. Autologous bone marrow transplantation with monoclonal antibody purged marrow for high risk acute lymphoblastic leukemia. Leukemia 1989; 3: 631–636
   PubMed Web of Science ®Google Scholar
• Arnold R., Schmeiser T., Heit W., Frickhofen N., Pabst G., Heimpel H., Kubanek B. Hemopoietic re-constitution after bone marrow transplantation. Exp. Hematol. 1986; 14: 271–277
   PubMed Web of Science ®Google Scholar
• Rowley S.D., Jones R.J., Piantadosi S., Braine H.G., Colvin O.M., Davis J., Saral R., Sharkis S., Wingard J., Yeager A.M., Santos G.W. Efficacy of ex vivo purging for autologous bone marrow transplantation in the treatment of acute nonlymphoblastic leukemia. Blood 1989; 74: 501–506
   PubMed Web of Science ®Google Scholar
• Fenaux P., Castaigne S., Dombret H., Archimbaud E., Duarte M., Morel P., Lamy T., Tilly H., Guerci A., Ma-Loisel F., Bordessoule D., Sadoun A., Tiberghien P., Fe-Gueux N., Daniel M.T., Chomienne C., Degos L. A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma. Blood 1992; 80: 2188–2195
   PubMed Web of Science ®Google Scholar